Skip to main content
. Author manuscript; available in PMC: 2020 Aug 9.
Published in final edited form as: Int J Cancer. 2019 Jan 15;144(11):2707–2717. doi: 10.1002/ijc.32006

Figure 2. DNA methylation characteristics associated with PAX3-FOXO1- and PAX7-FOXO1-positive RMS tumors.

Figure 2.

A, Volcano plot displaying differentially methylated probes between PAX3-FOXO1- and PAX7-FOXO1-positive RMS tumors. Red and pink dots denote hypermethylated and hypomethylated probes in PAX3-FOXO1- versus PAX7-FOXO1-positive tumors, respectively. CDKN1C promoter methylation (B) and RNA expression (C) levels in PAX3-FOXO1- and PAX7-FOXO1-positive RMS tumors. D, Correlation plot of DNA methylation versus RNA expression levels for CDKN1C in PAX3-FOXO1- and PAX7-FOXO1-positive RMS tumors. E, Representative CDKN1C immunohistochemical staining results in PAX3-FOXO1- and PAX7-FOXO1-positive tumors. Upper, CDKN1C negative staining in a PAX3-FOXO1-positive tumor; Lower, strong staining in a PAX7-FOXO1-positive tumor. Abbreviations: P3F, PAX3-FOXO1; P7F, PAX7-FOXO1.